Retatrutide 12mg
Retatrutide makes semaglutide look like a first draft. By targeting GLP-1, GIP, AND glucagon receptors simultaneously, it achieved 24% body weight loss in clinical trials — more than any other compound ever tested. It burns fat through three independent pathways while preserving lean muscle mass. This is the future of metabolic medicine.
About Retatrutide 12mg
Retatrutide has generated extraordinary research interest following Phase 2 clinical trial results published in the New England Journal of Medicine, demonstrating up to 24.2% mean body weight reduction at 48 weeks — the highest reported for any obesity pharmacotherapy in clinical trials. The triple-agonist mechanism activates GLP-1R (appetite suppression, insulin secretion), GIPR (insulin sensitivity, fat oxidation), and GCGR (hepatic lipid oxidation, thermogenesis) simultaneously. Research explores its effects on body composition, NAFLD/NASH, cardiovascular markers, and metabolic syndrome. Phase 3 trials are ongoing across multiple indications.
Full Research Monograph — 2 PubMed CitationsYou May Also Consider
The weight loss revolution — the same molecule in Ozempic that helps millions lose 15-20% of body weight by silencing food cravings and resetting appetite at the brain level.
- Lose 15-20% of body weight without willpower or starvation
- Completely eliminates food noise and constant cravings
Cagrilintide
5mgThe semaglutide amplifier — a long-acting amylin that pairs with GLP-1 drugs to supercharge weight loss. Part of the CagriSema combination that's the next breakthrough.
- Long-acting amylin analog for appetite suppression
- Pairs with semaglutide for enhanced weight loss (CagriSema)
AOD 9604
5mgThe fat-burning fragment of growth hormone — targets and destroys stubborn body fat (especially belly fat) without touching muscle, blood sugar, or hormone levels.
- Burns fat without affecting blood sugar or growth hormone levels
- Targets stubborn belly fat specifically